false 0001737287 0001737287 2025-01-23 2025-01-23

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 23, 2025

 

 

Allogene Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-38693   82-3562771

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

210 East Grand Avenue, South San Francisco, California   94080
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 457-2700

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   ALLO   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 23, 2025, Allogene Therapeutics, Inc. (the “Company”) and Timothy Moore agreed that Mr. Moore would be leaving his employment with the Company on February 28, 2025. Consistent with the terms of the Company’s Change in Control and Severance Benefit Plan, as a termination without cause, Mr. Moore will be eligible to receive certain cash severance and COBRA reimbursement benefits thereunder, subject to Mr. Moore providing the Company with an effective release and waiver of claims. The Company intends to enter into a consulting agreement with Mr. Moore, subject to mutual agreement of terms in the near future.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Allogene Therapeutics, Inc.
Date: January 29, 2025     By:  

/s/ David Chang, M.D., Ph.D.

     

David Chang, M.D., Ph.D.

President, Chief Executive Officer

v3.24.4
Document and Entity Information
Jan. 23, 2025
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001737287
Document Type 8-K
Document Period End Date Jan. 23, 2025
Entity Registrant Name Allogene Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38693
Entity Tax Identification Number 82-3562771
Entity Address, Address Line One 210 East Grand Avenue
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 457-2700
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol ALLO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Allogene Therapeutics Charts.
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Allogene Therapeutics Charts.